Market Place
Sourcing Support
Ardelyx Responds to Court`s Motion to Dismiss Decision
08 Nov 2024 //
GLOBENEWSWIRE
Ardelyx to Participate at 2024 Jefferies London Health Conference
05 Nov 2024 //
GLOBENEWSWIRE
Ardelyx Reports Q3 2024 Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
Ardelyx Presents IBS in America 2024 Survey Results at ACG
28 Oct 2024 //
#N/A
Ardelyx Shares Data On XPHOZAH® At Kidney Week
24 Oct 2024 //
GLOBENEWSWIRE
Ardelyx Launches Podcast For IBS-C Patient Community
22 Oct 2024 //
GLOBENEWSWIRE
Ardelyx Announces Derek Award To Recognize Kidney Disease Advocates
21 Oct 2024 //
GLOBENEWSWIRE
Ardelyx To Report Q3 2024 Results On October 31
17 Oct 2024 //
GLOBENEWSWIRE
Ardelyx Presents Data Supporting Xphozah In Chronic Kidney Disease
15 Oct 2024 //
GLOBENEWSWIRE
Ardelyx`s Review Article of IBS-C in Clinical Gastroenterology
09 Oct 2024 //
GLOBENEWSWIRE
Ardelyx To Participate At Cantor Global Healthcare Conference
05 Sep 2024 //
GLOBENEWSWIRE
Ardelyx Appoints Eric Foster As Chief Commercial Officer
08 Aug 2024 //
GLOBENEWSWIRE
Ardelyx Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Ardelyx Publishes XPHOZAH® Trial Summaries In Medical Journal
31 Jul 2024 //
GLOBENEWSWIRE
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
18 Jul 2024 //
GLOBENEWSWIRE
Ardelyx sues US health department over kidney disease drug
18 Jul 2024 //
PRESS RELEASE
Ardelyx, AAKP And NMQF Sue To Protect Dialysis Patient Access
17 Jul 2024 //
GLOBENEWSWIRE
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
02 Jul 2024 //
GLOBENEWSWIRE
Ardelyx Presents Data On Educational Needs For IBS-C Management
28 Jun 2024 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
30 May 2024 //
GLOBENEWSWIRE
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
22 May 2024 //
GLOBENEWSWIRE
Ardelyx Presents IBSRELA IBS-C Data At DDW 2024
21 May 2024 //
GLOBENEWSWIRE
Ardelyx Presents Additional XPHOZAH Data At NKF 2024
16 May 2024 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
14 May 2024 //
GLOBENEWSWIRE
Ardelyx To Present IBSRELA Data At Digestive Disease Week 2024
07 May 2024 //
GLOBENEWSWIRE
Ardelyx Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Ardelyx: XPHOZAH Data In Kidney Disease At NKF 2024 Meeting
01 May 2024 //
GLOBENEWSWIRE
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
18 Apr 2024 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
28 Mar 2024 //
GLOBENEWSWIRE
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive VP
25 Mar 2024 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
12 Mar 2024 //
GLOBENEWSWIRE
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
27 Feb 2024 //
GLOBENEWSWIRE
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results
01 Feb 2024 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
12 Jan 2024 //
GLOBENEWSWIRE
Ardelyx Provides Update on Commercial Momentum and 2024 Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
Ardelyx to Provide Company Update on IBSRELA and Host a KOL Discussion
03 Jan 2024 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
20 Dec 2023 //
GLOBENEWSWIRE
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
21 Nov 2023 //
GLOBENEWSWIRE
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA
15 Nov 2023 //
GLOBENEWSWIRE
Ardelyx Announces Departure of Board Member
13 Nov 2023 //
GLOBENEWSWIRE
Ardelyx to Participate at the Jefferies London Healthcare Conference
10 Nov 2023 //
GLOBENEWSWIRE
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
06 Nov 2023 //
GLOBENEWSWIRE
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor)
03 Nov 2023 //
GLOBENEWSWIRE
Ardelyx Reports Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
30 Oct 2023 //
GLOBENEWSWIRE
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA
23 Oct 2023 //
GLOBENEWSWIRE
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
18 Oct 2023 //
GLOBENEWSWIRE
US FDA approves Ardelyx`s kidney disease-related drug
18 Oct 2023 //
REUTERS
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital
17 Oct 2023 //
GLOBENEWSWIRE
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia
13 Oct 2023 //
GLOBENEWSWIRE
Ardelyx Shares Preliminary Data on Use of IBSRELA in Pediatric IBS-C Patients
04 Oct 2023 //
GLOBENEWSWIRE
Ardelyx Announces Publication of Positive Results from Trial of Tenapanor
28 Sep 2023 //
GLOBENEWSWIRE
Tenapanor for Hyperphosphatemia Approved in Japan
25 Sep 2023 //
GLOBENEWSWIRE
Ardelyx Showcased Data on Efficacy of IBSRELA for IBS-C at GHAPP 2023
11 Sep 2023 //
GLOBENEWSWIRE
Ardelyx to Present at H.C. Wainwright 25th Annual Global Investment Conference
08 Sep 2023 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
07 Sep 2023 //
GLOBENEWSWIRE
Ardelyx Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Ardelyx, Inc. Reports Employment Inducement Grants
27 Jul 2023 //
GLOBENEWSWIRE
